Muscle Strength Training in Lower Limb Amputee Patients

November 28, 2025 updated by: Gabriela Dell Elce, University of Gran Rosario

Effects of Muscle Strength Training in Lower Limb Amputee Patients

This study is a clinical trial that evaluates the best treatment option using a strength training protocol and an endurance training protocol in patients with lower limb amputations who use prostheses. The protocol consists of 6 weeks of strength training and 6 weeks of endurance training, with a 1-month washout period between the two.

Study Overview

Status

Not yet recruiting

Detailed Description

The assessments in this study focus primarily on strength, using a dynamometer and the 5 RM, functionality, using the AMP scale, mobility, using the TugTest, quality of life, using the WHOQOL-BREF, and perception of change, using the GROC.

Study Type

Interventional

Enrollment (Estimated)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with unilateral lower limb amputation
  • Transtibial and/or transfemoral amputation
  • Prosthetized
  • Aged 18 to 75 years
  • Who sign the informed consent form

Exclusion Criteria:

  • That they are unable to complete the initial assessment
  • That they undergo further secondary training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Muscle strength training

Strength training lasts six weeks, during which submaximal strength percentages ranging from 75% to 90% are worked on.

It is performed three times a week and follows a protocol consisting of progressive exercises for the large functional muscle groups relevant to the population being trained.

Strength training lasts six weeks, during which submaximal strength percentages ranging from 75% to 90% are worked on.

It is performed three times a week and follows a protocol consisting of progressive exercises for the large functional muscle groups relevant to the population being trained.

Active Comparator: Endurance training
Resistance training will be carried out for 6 weeks, 3 times a week, with exercises prescribed by a protocol with training characteristics defined by bibliography found in the ACSM.
Resistance training will be carried out for 6 weeks, 3 times a week, with exercises prescribed by a protocol with training characteristics defined by bibliography found in the ACSM.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Funcionality
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
It is assessed using the TUG test, which requires patients to get up from a chair, walk 3 meters, turn around, walk back to the chair, and sit down again. Patients will receive the following instructions: "Get up on the word 'go,' walk to the tape, turn around, walk back to the chair, and sit down."
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
Changes in quality of life
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
It is assessed using a self-administered questionnaire called WHOQOL-BREF, which provides a profile of the person's perceived quality of life.
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Maximum isometric muscle strength
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
It is evaluated using a dynamometer, in which three measurements are taken for each designated movement and the average of the maximum force and peak force is calculated.
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
Changes on Movility
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
It is assessed using the AMP functional rating scale (amputee mobility predictor).
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
Change in Global percepcion of change
Time Frame: assessments were performed at the end each protocol. day 18 and day 24
It is an assessment carried out using the Groc scale, which evaluates changes in perception.
assessments were performed at the end each protocol. day 18 and day 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Mauro S Barone, Ugr

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 30, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

September 22, 2025

First Submitted That Met QC Criteria

November 28, 2025

First Posted (Estimated)

December 3, 2025

Study Record Updates

Last Update Posted (Estimated)

December 3, 2025

Last Update Submitted That Met QC Criteria

November 28, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

If necessary or required, informed consent and data analysis will be shared.

IPD Sharing Supporting Information Type

  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lower Limb Amputation

Clinical Trials on Muscle strengh training

Subscribe